BMS-794833 NEW
| Price | $35 | $90 | $153 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: BMS-794833 | CAS No.: 1174046-72-0 |
| Purity: 99.69% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | BMS-794833 |
| Description | BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378. |
| Cell Research | GTL-16 cells are seeded into 96 well plates and incubated for 24 hours. BMS798433 is dissolved in DMSO at 10 mM and diluted with culture medium before use. Then BMS798433 is added to the cells for 72 hours. After that, MTS assay is used to measure the IC50.(Only for Reference) |
| Kinase Assay | Met kinase assay: BMS798433 is dissolved in DMSO and diluted by water before use. The reaction solution contains baculovirus expressed GST-Met kinase, 20 mM Tris-HCl (pH 7.4), 1 mM MnCl2, 1 mM DTT, 0.1 mg BSA, 0.1 mg polyGlu4/tyr, 1 μM ATP and 0.2μCi γ–ATP. Reactions are incubated at 30 °C for 1 hour and stopped by 8% TCA. TCA precipitates are collected onto GF/C plates using a universal harvester and the filters are quantitated using liquid scintillation counter. |
| In vitro | At a dosage of 25 mg/kg, BMS798433 exhibited complete inhibition of tumor growth in the U87 glioblastoma model. In the GTL-16 human gastric tumor xenograft model, treatment with BMS798433 for 14 days resulted in a Tumor Growth Inhibition (TGI) rate of over 50% within at least one tumor doubling time, with no significant toxicity observed during the period. |
| In vivo | BMS794833 inhibits the activation of the Met receptor in the gastric cancer cell line GTL-16, with an IC50 of 39 nM. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 87 mg/mL (185.6 mM) Ethanol : < 1 mg/mL (insoluble or slightly soluble) |
| Keywords | VEGFR | BMS794833 | Inhibitor | c-Met/HGFR | inhibit | Vascular endothelial growth factor receptor | BMS 794833 | BMS-794833 |
| Inhibitors Related | Ribociclib | Nintedanib | Regorafenib monohydrate | Sorafenib | L-Ascorbic acid 2-phosphate trisodium | Regorafenib | Sanguinarine chloride | Nintedanib esylate | Sorafenib tosylate | Lenvatinib mesylate | Pazopanib | Axitinib |
| Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Preclinical Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1g |
VIP2Y
|
shandong perfect biotechnology co.ltd
|
2023-08-14 | |
| $0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-12-30 | |
| $0.00/1KG |
VIP3Y
|
Wuhan Senwayer Century Chemical Co.,Ltd
|
2023-02-17 | |
| $1.00/100g |
VIP6Y
|
Career Henan Chemical Co
|
2019-12-20 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY